Some people don't just live in this world, they build the one we're about to live in. I'm Sophie Bai, the founder of BAI Biosciences. Every episode, I sit down with the people shaping how we live today and creating what's coming in the future.
My guest today wrote to 40 universities looking for a job and got no answers. Then he applied for a research grant nine times and all nine times got rejected. But today the world calls him the Edison of medicine, the most cited engineer in human history. And he is my professor, the SAB chair of my company, my mentor that I'm lucky to have had for the past 17 years, MIT Institute Professor, Dr. Bob Langer. Welcome.
Well, thank you for having me. It's great to see how well you've done.
Oh, thank you. Well, today we're going to talk about you. So, you know, besides or before all of the awards and accolades, the 40 companies you founded, the billions of lives you've touched, tell me or help our audience to understand the kid that grew up in Albany, New York.
Yeah. Well, I mean, you know, we lived in a small house in Albany and I, you know, with my mom and dad and sister and, you know, I went to public schools, you know, and, you know, I think I had a pretty normal childhood. I, you know, I did get some science toys like erector sets and chemistry sets and microscope sets.
When, how old were you at the time?
Well, chemistry I think I was 11. I think the erector sets I got a little younger. They kept improving them as they went on. You know, like the most advanced one was a six-foot robot.
But then they had rocket launchers and parachutes and all kinds of things. But those, they were all good, but mostly, you know, I played sports with my friends like football and baseball and, you know, that was a nice childhood.
So your dad ran a liquor store? A small liquor store?
Yeah, he did. He had a small liquor store on Delaware Avenue in Albany, New York. And, you know, he worked, you know, six days a week, didn't work Sundays, but he'd work six days a week, he'd work, you know, very hard. But I think he grew up in the Depression, and I think when you grow up in the Depression, he wanted to make sure that... he got to see a lot of people, you know, actually commit suicide and stuff like that because they lost all their money, and he wanted to have a secure livelihood for our family, for my sister and I.
And how did that impact you growing up? Did you feel any sort of influence from him?
Well, I did, but not necessarily from that. I mean, I respected that he worked hard, but when he'd come home, he'd play math games with me and stuff like that.
Was he also good at math?
He was very good at math. He actually was very good at English. He majored... he finished second in his class in Union and then went to Harvard and got a master's degree in English. And he would do the Sunday New York Times crossword puzzle really fast. I mean, I can't do it at all, but yeah. So he was a very smart guy. He skipped two grades.
Oh, wow. So, what influenced you to pursue a degree in engineering?
Well, you know, I'd like to tell you that I was really well thought out, but you know what happened was, you know, I was good in math and science and I was not good in anything else like English or French or things like that. And both my dad and my guidance counselor said, 'Well, if you're good at math and science, you should become an engineer,' you know. So I did, but I mean, I really didn't understand what engineers did.
And you studied engineering at Cornell and then you went to MIT for a doctorate.
Yeah. Yes, that's right. I got both degrees in chemical engineering at Cornell and then MIT.
I remember when I was just a freshman in your lab, you had those Langer Lab pizza parties, right? And you were telling us you were making really different choices after graduating MIT because you said a lot of your peers went to oil companies.
They did. And I thought I'd do that too. I thought, you know, that's what chemical engineers did. They had, you know, good jobs. I, you know, I'd never seen the country before that. I was 24 years old. I hadn't been west of Buffalo or east of Boston my whole life. And I went to like Texas and California. And I got quite a few, I mean about 20 job offers from those companies. But I wasn't excited about it. I kept wanting to do something that I felt would make a bigger impact on the world, for me at least. And so, you know, when I was supposed to be doing my graduate work, and I did do it, but, you know, I got involved in helping start a school for low-income kids in Cambridge, and I got very involved in creating new chemistry and math curricula, and I really liked that. And so one day I saw an ad at the City College of New York to be an assistant professor to do that, and so I wrote them a letter applying for a job, but they didn't write me back, going along with, you know, what you were saying in the beginning. But I liked that idea. So I found all the ads I could to do that. And, you know, maybe about 40 of them, and I wrote all those schools, and I don't think anybody wrote me back. I guess the thing was, you know, I think you have to be in a certain box, you know, and I wasn't in that box. You know, some people major in chemistry education or things like that. So I didn't get any of those jobs. So then I thought, what other way could I use my chemical engineering background to help people? And I thought about medicine. And so I wrote to a lot of hospitals and medical schools who also didn't write me back. But then one of the people in my lab said, 'Well, there's a surgeon named Judah Folkman at Harvard and Children's Hospital.' And they said, 'Sometimes he hires unusual people.' So I wrote him and he was nice enough to give me an offer. And so I went there. I was the only engineer in the whole hospital, but that changed my life.
Was the curriculum at MIT at that time very petroleum engineering focused for chemical engineering? Did you learn any of the biology or medicine related topics at all?
First, none of it was petroleum engineering. It was like standard stuff like thermodynamics and heat and mass transfer and industrial chemistry.
I remember even my class we learned so much about fracking, distillation columns, and even the final year project was if you were to start a new fracking project, you have billions of dollars, where would you start?
Right, right. But what happened was in 1974, when I was, you know, looking for a job, when I got my doctorate, there was this gas shortage. So if you lived in the Boston area in 1974 and you had a car, you'd literally have to wait in line for two hours to get your tank filled up.
And the consequence of that was that any chemical engineer got a lot of job offers. I got four job offers from Exxon alone. That was interesting. I mean, to see, but it was just... but it is a pretty standard curriculum, I think, for graduate school.
I remember at the pizza party you told us that during one of the interviews, the interviewer said if you can increase the yield by 0.1%, then that could lead to billions of dollars of profit, but that kind of pushed you away from the industry instead of making you more excited about it.
Yeah, because 0.1%, I mean, that's not what I want to do. And I didn't know what I did want to do, but I could see 0.1%... I mean, you know, that I didn't want to spend my life doing that. I just didn't want to do something incremental, and I felt that would be incremental.
So not the amount of money would interest you at all at that time.
Yeah. Well, you know, it's kind of funny, you know, when I look back at my life, you know, I had a stipend, I think, at MIT of, I think it was $240 a month.
Oh, wow.
Do you know, do you remember how much I was making working as a research associate as an undergrad here? I remember... $8 an hour.
Well, that's right. So we're in a similar boat. So, you know, but so what happens is I took by far the lowest paying job, but I was so used to spending no money.
That I think I got like $13,000 or $11,000, you know, a year. And when I was at the hospital, so I'd make like $1,000 a month. And I just wasn't used to spending money. So the big differential, you know, I mean, now I think I don't know what we spend, you know, of course with three kids and two grandkids and my wife, but, you know, it was actually okay. I mean, it's nice to have money, but the oil companies, they paid, you know, really good salaries, but I wasn't thinking about it from that standpoint. You know, money wasn't the driving force for me. And I was doing something that I felt would make me feel good, you know, would make me feel like I was making an impact on the world.
So you said you felt like you didn't fit anywhere, right? Because engineering felt like what you wanted to do was medicine, and medicine felt like you were an engineer and you didn't belong to medicine. So what did Judah Folkman see in you that others didn't?
What Dr. Folkman said, what he was looking at, he had this theory that if you could stop blood vessels, you could stop cancer. And he further said that it was mediated by chemicals, and people didn't agree with him. You know, he got criticized for that. And he said people have been trying to solve this issue for a long time, and everybody had kind of conventional backgrounds. And what he said, well, you know, I had done, you know, reasonably well, but I didn't have a conventional background, you know. And so he said, well, you know, he was going to take a chance because he felt I was different. And, you know, so yeah, and so it worked out.
And you start working on the angiogenesis part of how do you stop the blood supply to the tumors, right?
And walk me through those years where I imagine because that was such a new concept at the time, were your colleagues or people in the field supportive, critical, how were they thinking of the work you were trying to do that, you know, led to the polymer work you were doing?
Yeah. So what I did was two things. One was try to isolate something, an extract that could stop blood vessels and show that you could really stop blood vessels. To do that, we had to create nanoparticles or microparticles that could deliver large molecules. So if I looked at my colleagues, I mean, say my age or even my advisor, you know, at MIT, I think they said, well, why would Dr. Folkman hire me, you know, to do that? And they said, well, you know, he must be crazy and I must be crazy because why would I go to a hospital and make no money or make very little money and do something that I wasn't qualified to do maybe. But anyhow, so as I do that work, people also criticized it. You know, when people said that it wasn't possible to deliver large molecules from little particles, and these were very famous people that he talked to. I mean, he asked people like Nobel Prize winners. There was one company that he was on the advisory board of called ALZA. In fact, in 1974, they were the only company in the world doing advanced drug delivery systems. Now, everybody does it. But so he was on their board and he asked them, and they just said that, you know, that would be impossible. And even after I did it, a lot, I mean, people just said, you know, it couldn't be right. I mean, people would ridicule the work.
So when the Nobel Prize winner said that what you were doing is impossible, how did that make you feel?
I think even though people say something's impossible, I felt like I wanted to solve the problem because we needed to solve that problem if we were going to solve the blood vessel problem. And I also felt like a loyalty to Dr. Folkman. I mean, he had hired me. He entrusted me. And so I, you know, I did hundreds of experiments, all kinds of different designs and materials, polymers, lipids, everything. And, you know, the first 200 didn't work. But eventually...
And each of those experiments takes days if not weeks, right?
Yeah, yeah, yeah. They do. It was a lot of work, and but, you know, eventually I did get something to work. I didn't fully understand it at the time, but I could see that the molecules were releasing. I had developed these little gels I could put them on, and if they released certain enzymes which were big molecules, you'd get a color change. So I could see eventually that was my test. Either normally one of two things would happen. Either the color would never change because something didn't come out, or it would change after like a minute or two because it came out right away. But eventually I took these things and, you know, and I kept testing it day by day by day, and one of them lasted for over a hundred days. So that made me see with my own eyes that something was going on.
So when you saw your experiment finally work, were you excited?
Yeah, I think I was. You know, it was a long time ago. It was 50 years, but I wasn't sure what was going to happen. And the fact that that could finally happen, that was exciting. And we also used those to stop blood vessels, and I could see that with my own eyes too. And that was exciting.
And then you presented your work as a postdoc at a symposium. What happened then?
Yeah. So I was 27 years old and I practiced that talk for many weeks. I was always afraid of speaking because I did a terrible job in eighth grade, and so I got up and, you know, so I was by far the youngest person there, and they had a lot of pretty well-known chemists and chemical engineers there. When I got up and I gave the talk, you know, I thought I didn't stammer too much or forget too much what I meant to say. So I thought that they would be encouraging, but they weren't. A lot of them came up and they said, you know, we don't believe what you said.
So they just said in your face that they didn't believe what you said.
And how did you respond to that?
Well, I said, 'Well, we did,' you know, and we had the data, you know, but people thought it was like an artifact. So that, you know, made me realize... and they said, well, how could it work? I tried to do over the next few years experiments to show how it did work, to understand that better. But, you know, it makes you feel not very good.
Yeah. Imagine 27 years old presenting your work that you have done for multiple years, and then nobody believed you.
Yeah, that is true. Yes, I remember that. And, you know, it was discouraging. I mean, but, you know, I hung in there.
Did you have any moment thinking that maybe this is not going to work out, maybe you should do something else?
I've had that happen several times in my life. Not necessarily just because of the science, you know, but I just didn't know, you know, where my career was going. I didn't have any clear ideas, you know, at different points. So I thought, yeah, maybe take a year off and work in an ice cream parlor. I like ice cream.
Yeah. So I stuck with it. But sometimes, you know, you get depressed, and when I tried to get grants, I didn't do very well in that either for a long time. My first nine were rejected, and that was pretty depressing. I mean, but I don't give up that easily. So I kept trying.
And finally, when you were applying for faculty positions, nobody was offering you jobs. No chemical engineering department was offering you jobs.
That's right. You know, well, what happened is, you know, so I had papers in Science and Nature, you know, which for a postdoc I thought was very good.
That's amazing. And this was 1976 papers.
Yeah.
And so I did get interviews. I got interviews at like Stanford, Caltech, Minnesota, which was at that time ranked number one in the country.
For chemical engineering.
For chemical engineering. Yeah.
But, you know, when I went there, I think people thought what I was doing was interesting maybe, but they didn't think it was chemical engineering. You know, I was doing this bio... I was doing experiments. I was doing biological stuff. And they said, well, you should be doing mathematical modeling or energy or, you know, but something that was chemical engineering. So in the end I didn't get any of those jobs, but then I did get a job in a nutrition department.
Yeah, was it a newly formed department at that time, nutrition? Because it doesn't exist today, I guess it turned into Course 20.
Yeah, so you're right, it's Course 20. It wasn't that new. What happened with that department, and it was actually ranked number one in the world in nutrition, you know, when I joined it, but the head of it, Nevin Scrimshaw, I mean, he was probably one of the top nutrition people in the world. And he was on that ALZA board too. And so Dr. Folkman knew him. He introduced me to him. And so he offered me a job. He was the kind of person, Nevin Scrimshaw, he didn't care what anybody thought, including everybody in his department. So he offered me this job. That was by far the best, you know, job that I got, and so, I mean, maybe it was the only one at that time.
But you weren't working on nutrition-related...
Right, but that department, it was a very interesting department, and this is now 1977, and they had like five areas. Nutrition was one of them, food science was another, but they had biochemical engineering, they had brain, they had what they called neuroendocrine regulation, and they had toxicology, and they combined all of them into this nutrition and food science department. And I still, even doing what I was doing, I didn't probably fit in, but I think they felt, or Nevin Scrimshaw felt, that I would do good things, and that's what... so he hired people to do that. He would take chances, and so, you know, I joined that department.
But shortly after you joined, he left.
That was pretty discouraging. So a lot of people then wanted me to... so, and not, yeah, I mean, so that wasn't so good.
And there is a dinner at a Chinese restaurant after he left with the faculty of that department.
So walk me through what happened at dinner.
Well, first what they did is in that department they had this idea that all the junior professors should give talks, and they made it sound like it was a nice thing, but they gave everybody a hard time. And, you know, when I had this dinner, one of the professors, he was a pretty famous guy, and he was smoking a cigar, and he blew a smoke in my face and told me my ideas on drug delivery, you know, that didn't make any sense, and I should start looking for another job. So that wasn't... that was also not very good.
That was in front of other faculty members.
It was, I don't know how many there were, but one time much later in my life when I got this award, Mike Marletta, who's a very good friend of mine, and he was on the faculty then, he became chair of the chemistry department at Berkeley and member of the National Academy of Sciences, and yeah, he was... so he actually told that story. You know, so he obviously had to be there. He was, you know, he said, well, one night I went to this dinner with Bob and a lot of senior MIT faculty members, and he said there this professor, you know, older professor was smoking a cigar, and he blew a cloud of smoke in my face and said, 'You better start looking for another job because these drug deliveries, you know, not going to work.'
And how were you feeling, reacting in that moment?
I was getting used to a lot of people not thinking what I was doing was ever going to work. But I think what was helpful to me was Dr. Folkman, he had that same experience. You know, people told him his stuff wasn't going to work. And so I was... and I just maybe when I was younger, I had this idealized view of science that scientists were nice people and they would always want to encourage you. But I started to realize as the time went on, and by this time I'd been working, you know, for maybe four or five years, first as a postdoc and now as a professor, and I realized scientists weren't always so nice. Then they'd often say things that were very negative and very discouraging. So I don't want to say I was getting used to it, but I certainly knew that that was common enough that people would... I think people were very competitive and things like that.
And how were you able to keep all of those negative voices out of your head?
Well, I don't know that I did keep them out of my head. I think I accepted that people were saying that I couldn't do this or that this was wrong or that this wouldn't work. But I felt like I had seen it with my own eyes that it did work. And I also felt it was important. I felt both the blood vessel work was important and I felt the drug delivery work was important. So I wasn't going to stop. And then, you know, also what was very good for me was when I did go to MIT, students really liked what I was doing. You know, I had a lot of students come to me and they'd want to work in the lab, and they all felt it was important. I mean, they were much younger and maybe they don't know as much as some of the older professors, but that kind of... I liked that I was helping them, and, you know, and so that all made a difference to me. And I always, I think what's nice about being a professor is when one thing doesn't go well, because you're doing a number of different things, some others do. So I like teaching. I was good at it, and I like to think, and I'd get satisfaction from helping students. So even if the research wasn't going well, I felt like the experience that I was having at MIT, you know, that had pluses and minuses, but I guess I'm kind of an optimistic person. So I would try to focus more on the things that made me happy, and the fact that I was helping students, that made me happy.
How do you differentiate stubbornness versus high conviction?
It's a good question, and I don't think there... and probably there's a fine line. I don't know that I can even make that distinction. You know, it's in a way it's a judgment call, and I felt that I did have high conviction because I felt, a, what I was doing was important, and, b, that I'd seen some of these things work with my own eyes. But, you know, I was stubborn too. I mean, I've always probably been stubborn. My parents would tell me that. And so I don't know that I can really make that distinction. Sometimes, you know, you keep trying. I probably try more, you know, and then maybe sometimes I should stop sooner. But...
Have you ever wondered in the back of your mind that what if you took the oil company job?
Yeah. Well, Dr. Folkman, he had a... you know, people asked him that, and he said, well, if... because, you know, the work I do, right, we can make drugs last for a long time, and so he said, yeah, if Bob went to an oil company, then we'd be getting our gas tanks filled up once a year.
That would be a great thing, or a long-lasting battery in the same...
Yeah, but I don't know what would have happened, you know, but that was what he said. But I'd like to think that if I worked at one of those, I would have done okay too. Maybe I wouldn't have done the conventional things. But I'd like to think that, you know, I mean, I certainly did think about those companies while I was there for the interviews.
But you never thought of, okay, maybe it's time to quit.
A little bit, you know, like I said about the ice cream parlor, you know, a little bit. But I sort of... I liked enough about what I was doing, like I say, the teaching, and I believed in the research. So I wasn't... and I, you know, I had some good friends actually. I mentioned Mike Marletta, he was in that department. Alex Klibanov was another very close friend of mine. I mean, they both still are. And, you know, we'd get together every Saturday for lunch and trade notes, have yogurt lunches, and I think that also helped, you know, because you have a camaraderie. I really didn't have people in that department for the most part, you know, like a mentor or something. I mean, Dr. Folkman was a mentor, but the two of them as good friends, that helped, I think.
Yeah. You said Dr. Folkman always believed anything is possible. Was that dissolute to you, or was it something that you always had when you grew up, that you believed everything was possible, or was that influenced by him?
I don't know what I thought, you know, about anything was possible, but certainly when I saw him doing that and him standing up in the face of a lot of criticism, you know, it certainly made me think... I really respected that, you know, he got criticized a lot, and I felt like he... and he had all kinds of ideas, not just he was a surgeon, but he had ideas on everything, and so I just felt that was a very good attitude, to think that almost anything was possible from a scientist.
Since you had such a hard time getting government grants, you start to think about other ways to be able to get money to fund your research or fund your lab, and then you start filing for patents. Is the goal for filing patents to help get financial interest from the industry so that they could fund your work?
Yeah. Well, that's an interesting question. So first, you know, I had a very hard time for a while getting government grants from like the National Institutes of Health because they said I was an engineer and I didn't know any biology or oncology. But then what I did is, after a lot of rejections, nine rejections straight, I started making up sections that I said relevant experience of the principal investigator and other things. And finally I started getting them. We also filed patents. Dr. Folkman... I really didn't know much about patents back in the 1970s when I was with Dr. Folkman, and we got, you know, the delivery systems. You know, Children's Hospital, which a lot of people would say it's the best children's hospital in the world, they didn't have any patents either, but he said we should file for one. So we did, and of course it got rejected a lot too, but eventually we got it. But at any rate, I kind of felt like, well, we should file for patents. Patents incent companies, I thought, to want to develop what you've done. And so I would file patents, and of course I've kept doing it. And a lot of those companies actually that I thought might use it didn't. I mean, they'd license it. They, you know, and I think after 10 years of doing this work, we finally got a patent, and I got asked to consult and be an advisor to two multi-billion dollar companies, one in animal health and one in human health, and they wanted to license our patents, and they were going to develop these things, and I thought that was great, but, you know, they kind of just gave up after a year or two.
Eli Lilly was one of them. And it's a great company. Of course, I don't know that it was as great in 1984, but they were interested in delivering insulin. And the other was International Minerals and Chemicals, but, you know, it was frustrating. And then Alex Klibanov, who I mentioned to you before, he said, 'Bob, we should start our own company.' So I was able to get those patents back. We started a company with several of my students, and we've kept doing that. You know, we've probably started over 40 companies. We've, I think, licensed or sublicensed the patents to over 400 companies. And those patents, you know, they would end up making a big difference because they provide an incentive for investors to come in.
Yeah, because you're protected to prevent your competitors copying what you have created. But even, you know, after years of trying to finally get the patents being granted, then you applied for an NIH grant, you got rejected again.
Yeah, I got rejected lots of times. But that's common, you know, really. I mean, I got rejected on patents. I got rejected on grants. But I mean, I'm not the only... that happens a lot. You know, I think the odds are that you're going to get rejected on both of those. In fact, on patents, people say if the first patent gets issued right away, you haven't made it broad enough, you know. So on grants, I mean, that's... I don't know what NIH... for a while they were funding like the best 10%. So the odds are you're going to get rejected. I mean, at different times in history they've gone up to 20, maybe even 30%, but the odds are you're going to get rejected. So I accepted that, though, like you say, at one point in my career I got pretty good at getting them, but, you know, lots of times I get rejected.
Yeah. So I actually drew a timeline of all the rejections you've had. So starting from 1974 after the doctorate at MIT, then it was 40 job rejections.
Then postdoc at Dr. Folkman's lab, then all the nine grants were rejected, and then the faculty position you're trying to apply, all chemical engineering programs rejected you. Then you couldn't get government funding, so you turned to industry and filed patents so that you could get the industry interest to fund your work. But even Eli Lilly of the world, they lost interest after the first trials weren't successful, so that pushed you to find smaller companies, Nova Pharmaceutical.
And that was the brain cancer treatment, right?
You know, you see smaller companies are more committed to innovation and trying to make things work.
And then in 1987, you started your own company, Enzyme Technologies.
And then 1988, you started your second company, Neomorphics.
And then in 1988, finally, after the commercial success and the market and academia acceptance, you finally felt secure to get a full faculty position at MIT, and that's 15 years from 1974 to 1988.
Yeah. Well, I had a rocky start.
So I guess 15 years of predominantly rejections. What kept you going?
Well, I believed in what I was doing. I felt it was important, and, you know, like I say, I didn't agree with people who told me it didn't work because I'd seen it with my own eyes, but I felt it was important, you know, and I suppose that was what kept motivating me, you know, that I felt if we succeeded at doing these things, it would help a lot of people.
And that led to the Gliadel.
The FDA approved, or the first of its kind, still the only of its kind.
The delivery system that can deliver chemo directly to the brain.
So when you learned what you have worked on in the lab finally made it to the patients, how did you feel?
It makes you feel wonderful. It makes you... and I met some of the patients, and I mean, it makes you feel... Of course, I worked on that with Henry Brem, who later would become neurosurgeon-in-chief at Johns Hopkins. But, you know, that's what I wanted to do. I mean, that was making an impact. So that meant a lot.
And that was 20 years after your Nature paper.
So it took 20 years from your work published in Nature to that become a product being approved by the FDA.
That's true. That's true. But medicine is slow. Actually, the angiogenesis stuff, the blood vessel stuff, that took 28 years from our paper. I mean, again, it wasn't me that would end up developing those drugs. Genentech did. But 28 years from proving that you could do this and developing assays that would enable you to do it, medicine is slow.
And do you think medicine should be this slow?
Well, you know, people say that first do no harm. You know, that's like the Hippocratic Oath. And I think that's part of what the FDA, I mean, in general, would say, that you want to make sure that things are safe. And so I do think you should make exceptions sometimes, but probably not that often. I mean, two exceptions that I've seen, and I think they were both right, were AIDS drugs. You know, people were dying of AIDS, and when they're dying, you know, they accelerated approvals, and, you know, some of those people would do better. And of course the other time, and I'd end up being personally involved in that, was the COVID vaccine, because, I mean, millions of people were dying. So they, you know, granted emergency use approval, and I think you can do things like that, but always I think what you keep in mind, or what should be kept in mind, is the risk-reward ratio, you know. So, I mean, no medicine is without risks. I mean, people may point to those risks, and they may point to side effects or whatever, and that's true, but death is a worse side effect than, you know, not feeling good or even some type of disease. So I think that when people are dying, you can make an exception, but for a lot of diseases they won't, because they, you know, they won't allow it because it can cause harm. And of course the classic example of that that they would go over is like there was some drug that people got in the US and that the US didn't approve, and people in Europe did, and that little babies would grow up with deformed limbs and things like that.
You once made a comparison between investing in a company like Facebook versus investing in companies like biotech companies or drug companies, because the return you're able to see from software companies tend to be much faster than investing in creating a drug, but then you can't really cure cancer by investing in software companies.
Right, I agree with you. Well, I mean, again, I wasn't motivated... I mean, people certainly have made money in medicine and in biotech. You know, I've made money too. But it's not, you know, it's not that that was the point. The point, you know, was always about helping people.
And because that was what would give me satisfaction. And Facebook, you know, it's... I mean, obviously they've been incredibly successful, but, you know, to me, I think the two things I value for people are making them healthy and making them happy, giving them good education. Those are always the things...
that I would spend my time on. You know, not that I'm anything great, but I just that would make me feel good if I knew I was doing that. So, I do.
Yeah. I mean, you taught us, right? Like making an impact. I think nothing is more satisfying than saving somebody's lives.
Yeah. And improving their life and saving them and improving them, and you know, I think research does that.
And I remember in our senior capstone project you were teaching us in the class, asking us to create using hydrogel to create a treatment for type 1 diabetes. That was probably the most interesting, most difficult and most rewarding class that I've taken at MIT. But we got the highest grade. [laughter] Putting that aside.
Well, you were smart. [gasps] But it was so incredibly interesting where in a class, an undergraduate class, that we were creating very realistic drugs or delivery systems, or the implant that we created that can actually, you know, we believe could potentially down the road be truly a treatment for the patient. Not something that you learn from a textbook that oh everything is theoretical lives in those pages, but something actually is useful, can be very, very useful using what we have learned in school.
Yeah. No, well that and that was an interesting class to teach and actually to develop. I, John Kikinis and I developed that class from scratch and I, you know, I taught it for many years. I still give a lecture in that class on patents, but you know, other people teach it.
Yeah. And I found a photo. Well, back then there was no social media. I found one. [laughter] [gasps] This was our paper and we called it the novel glucose-responsive rechargeable insulin-secreting implant for long-term controlled release. It's a mouthful. And when we during our final presentation, it was my birthday. So, the whole class bought me a huge, huge bottle of vodka.
That's fantastic. [laughter]
And then we drank it after our final presentation.
So, but that was, you know, one of the many exciting moments at MIT. MIT is really hard, but that was one of the highlights of, you know, us at least trying to solve a very real, very, very serious health problem.
Well, that's a big problem and diabetes, you know, affects an awful lot of people. But yeah, that well I really liked that class and you know I'm very glad to hear that you liked it.
Oh, I loved it. So you know we talked about the Gliadel in terms of really being a breakthrough treatment for a lot of the brain cancer patients, but you're working on something related in the brain realm in your lab right now. So tell me about that.
Yeah. Well, Li Wei Tsai, who's head of the Picower Institute, she's stepping down now, but she asked me a number of years ago, we write a grant to see if we could actually make a personalized brain on a chip in in in
It isn't because we did it. And you know, and I had a really good postdoc, Alice Stanton. She actually worked well she went to Princeton and worked for Marc Tessier-Lavigne when he was president of Rockefeller. Then she worked with Fan Yang who was for graduate school. Fan was one of my postdocs at MIT and anyhow so when we were hiring people you know we hired her and she did an amazing job and she led this work and there were other people like Adele and others that were working on it but with her.
So you know so what we were able to do is like I could take your cells convert them to what's called an iPS cell and then convert each of those to the six different brain cell types and Alice did a lot tremendous amount of work finding a matrix that would help them reorganize and actually make a blood brain barrier and everything else and you know we published that in PNAS late last year and she actually went to Massachusetts General Hospital. They have a new neurology institute and she was the first person they'd hire to be assistant professor. So, you know, we're still working together with her and Li Wei on these issues, you know, and we're looking at maybe you could find new drug targets for Alzheimer's or ALS or other brain diseases.
But the beauty of having, you know, the brain on a chip, it's almost impossible to do experiments on humans. Obviously, nobody's been able to do much with Alzheimer's. It's also when you do animals, they're not the same as humans. Their brains are different. So here, you can literally make thousands of these and you could do high throughput testing and so you can do experiments on a human system that mimics a human system. I mean we showed that it mimics, you know, blood brain barrier transport and other things. So it really gives you the opportunity to maybe find new targets to find better ways of getting drugs across the blood brain barrier and things like that. So that's been exciting.
So to the audience who are not scientists, it's basically a piece or small piece of the working brain that Alice in your lab was able to assemble all six major types of brain cells all together for the first time and for people to actually or for researchers to study the different part of the cells how they're behaving functioning, you know, trying to learn about the brain diseases because we understand so little about our brain.
That's right. Yeah. So what you said is perfect. You know, you can study the brain cell types. You can even make diseased brains. You can see how cells interact with each other. You can look at transport through the brain. So, yeah, there's many things that enables you to do that you really couldn't do very easily before.
Do you think the fact that we are so bad at treating brain diseases including Alzheimer's, Parkinson's as well as the brain cancers, the fundamental issue is that we don't understand our brain.
I agree what you said is exactly right. We don't I mean we understand some things but a lot of things we don't. The brain is not well understood.
This work is remarkable because it is enabling us to be able to study brain outside of a living patient.
Yes, that's exactly right. And you can do like when you were talking about things before and how slow they are, you know, this can be done fast. I mean, you can do thousands of experiments. We call it high throughput.
And another thing I learned from reading those work is that the cells were from the iPS cells that were from one patient donor's skin.